Scholars Central

Conference abstractPublished 23 Nov 2012

Quality-by-design approach to analytical method development

Authors: Yogita Prajapati

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Quality-by-design was first described by Joseph M. Juran, is a systematic approach to drug development, which begins with pre-defined objectives, and uses science and risk management approaches to gain product and process understanding and ultimately process control. The FDA has recently begun to advocate the QbD methodology for the pharmaceutical sector. More companies in the pharmaceutical industry today are in the need of adopting the principles of Quality-by-design (QbD) to the development of analytical methods in addition to the development of manufacturing processes. As such, both industry and regulators recognize the benefits of adopting a QbD approach to drug-product development and manufacture, with key concepts described in the International Conference on Harmonization (ICH) guidelines, Q8 (R1) Pharmaceutical Development, Q9 Quality Risk Management, and Q10 Pharmaceutical Quality System. Drug development using the principles of QbD can be introduced as two key concepts that further aid in implementation. The first concept is the ?design space? that generally involves the identification of the critical attributes for the input materials, the process, and the final product. Another important concept is that of the ?control strategy? which is to ensure the final quality of the product. Some of the concepts are more applicable than others, and some have been advocated by many method development experts for some time, but modern technology has created an opportunity to revisit strategies for creation of chromatographic methods in particular, and it is certainly interesting to investigate the new opportunities in the context of Quality by Design. The ultimate goal is to highlight the QbD concepts and terminology can be applied to analytical methods and to suggest how adoption of a QbD approach might be used to develop more robust analytical methods and effective control systems.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Pharmaceutical Regulatory Affairs: Open Access.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalPharmaceutical Regulatory Affairs: Open Access
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Yogita Prajapati”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels